Healthcare
Live Price
Offline$184.71
+0.49% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
BeiGene, Ltd. (BGNE) is a Healthcare stock with a market cap of $20.21B. The stock last traded around $184.71. Baseline metrics include revenue growth of +40.2%, EPS growth of +659.6%, a dividend yield of 0.0%. What stands out right now is revenue +40.2%, EPS +659.6%, free cash flow +240.6% with operating margin 8.4% and ROIC 4.8%. Valuation already assumes a fairly strong business story at P/E 171.9 and price/sales 6.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines BGNE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
BGNE
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
BGNE Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BGNE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.2B
-16.9% YoY
FY Net Income
-$1.4B
+29.5% YoY
Free Cash Flow
-$1.6B
+17.9% YoY
Revenue Growth
+40.2%
EPS Growth
+659.6%
Gross Margin
86.9%
Net Margin
5.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5.3B | 3.8B | 2.5B | 1.4B | 1.2B |
| Gross Profit | 4.7B | 3.2B | 2.1B | -511M | -448M |
| Operating Income | 447M | -568M | -1.2B | -1.8B | -1.4B |
| EBITDA | 617M | -396M | -1.1B | -1.7B | -1.4B |
| Net Income | 287M | -645M | -882M | -2.0B | -1.4B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.5B | 2.6B | 3.2B | 3.9B | 4.4B |
| Total Assets | 8.2B | 5.9B | 5.8B | 6.4B | 8.6B |
| Total Liabilities | 3.8B | 2.6B | 2.3B | 2.0B | 2.4B |
| Shareholder Equity | 4.4B | 3.3B | 3.5B | 4.4B | 6.2B |
| Total Debt | 1.1B | 1.1B | 930M | 891M | 695M |
| Net Debt | -3.5B | -1.5B | -2.2B | -3.0B | -3.7B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1.3B
+13.2% YoY
Capital Expenditures
315M
+32.9% YoY
Free Cash Flow
1.6B
+17.9% YoY
Key ratios
Gross Margin
86.9%
Operating Margin
8.4%
Net Margin
5.4%
ROE
7.3%
Debt / Equity
0.46x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.